SCHEMBL4386926

SCHEMBL4386926

Cc1nc2cc(NC(=O)N3CCN(c4ccccc4F)CC3)ccc2s1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 3/20 0.59
MAPT P10636 8/20 0.59
ALDH1A1 P00352 4/20 0.59
HSD17B10 Q99714 3/20 0.59
KDM4E B2RXH2 3/20 0.59
HTR1A P08908 1/20 0.56
HTR1D P28221 1/20 0.56
HTR1B P28222 1/20 0.56
HTR2C P28335 1/20 0.56
HTR6 P50406 1/20 0.56
SMN1; SMN2 Q16637 5/20 0.55
RAB9A P51151 2/20 0.55
TSHR P16473 4/20 0.54
TP53 P04637 1/20 0.54
PANK3 Q9H999 1/20 0.53
KMT2A Q03164 3/20 0.53
MEN1 O00255 2/20 0.53
LMNA P02545 2/20 0.52
ALOX15 P16050 2/20 0.52
GFER P55789 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4386184 0.89 SMN1; SMN2 (0.54) POLBMAPTALDH1A1HSD17B10KDM4E
SCHEMBL29178288 0.78 POLB (0.81) POLBMAPTALDH1A1KDM4EHTR1A
SCHEMBL3716149 0.75 POLB (0.75) POLBMAPTKDM4EHTR1AHTR1D
SCHEMBL19149436 0.75 KDM4E (0.56) POLBMAPTALDH1A1HSD17B10KDM4E
SCHEMBL19149015 0.74 KDM4E (0.57) POLBMAPTALDH1A1HSD17B10KDM4E
SCHEMBL6961396 0.73 PANK3 (0.63) POLBMAPTALDH1A1HSD17B10KDM4E
SCHEMBL5798843 0.71 RAB9A (0.65) POLBMAPTALDH1A1HSD17B10KDM4E
SCHEMBL19174266 0.71 FAAH (0.51) POLBMAPTALDH1A1KDM4ESMN1; SMN2
SCHEMBL19174229 0.71 KDM4E (0.53) POLBMAPTALDH1A1HSD17B10KDM4E
SCHEMBL17925868 0.71 TRPV1 (0.50) POLBMAPTALDH1A1HSD17B10KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1606289-B1 CARBOXAMIDE DERIVATIVES GLAXO GROUP LTD (GB) 2009-12-02 EP claimed
EP-1606289-B1 CARBOXAMIDE DERIVATIVES GLAXO GROUP LTD (GB) 2009-12-02 EP disclosed
US-7531558-B2 e.g. 6-(4-Fluorophenyl)-2-methyl-N-(2-methylbenzothiazol-5-yl)nicotinamide; vanilloid (capsaicin) receptor modulator; analgesic; chronic, neuropathic, postoperative, postrheumatoid arthritic, osteoarthritic, back, cancer, dental pain, algesia, neuralgia, migraine, neuropathies, ischaemia GLAXO GROUP LIMITED (GB) 2009-05-12 US disclosed
US-20060148855-A1 Carboxamide derivatives GLAXO GROUP LIMITED (GB) 2006-07-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060148855-A1 Carboxamide derivatives CNR2, CNR1, SUCNR1 POLB 2302/4885MAPT 2329/4885ALDH1A1 1895/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.